Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Chris Varma
|
| gptkbp:developedBy |
small molecule drugs
|
| gptkbp:focusesOn |
precision medicine
drug discovery cancer therapeutics |
| gptkbp:foundedIn |
2019
|
| gptkbp:founder |
gptkb:Brian_Finrow
Chris Varma |
| gptkbp:fundedBy |
gptkb:Series_B
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Frontier Medicines
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Polaris_Partners
gptkb:Blackstone_Life_Sciences gptkb:Eli_Lilly_and_Company gptkb:DCVC gptkb:Deerfield_Management Section 32 |
| gptkbp:notableProject |
covalent drug discovery platform
|
| gptkbp:targetMarket |
immunology
oncology |
| gptkbp:technology |
gptkb:machine_learning
chemoproteomics |
| gptkbp:website |
https://frontiermeds.com/
|
| gptkbp:bfsParent |
gptkb:Daniel_K._Nomura
|
| gptkbp:bfsLayer |
7
|